



Antibody development custom services



Develop antibodies with specific assay goals in mind

Develop antibodies screened for performance

A custom strategy is the key to ensuring the best performing antibodies for any application.

BBI offers expert partnership in the development of monoclonal or polyclonal antibodies, antibody production and purification services under ISO 13485:2016.

An industry-leading advantage, 'MultiPure' allows customers to see assay performance data not only sooner than in typical development but also for dozens of antibody candidates. This early-in-development characterization in the desired end-application of a larger number of clones significantly speeds up finding the clone that meets your needs.

The experience to anticipate customer needs

Immunoassay goals have evolved and become more complex in recent years. There is no substitute for the experience in identifying project risks. A project initiation meeting gives customers an opportunity to define specific assay goals and gain insight from the experience of our technical team, on the best approaches to challenging antibody applications, including IVD assays, anti-idiotypic projects, biomarker discovery and anti-drug assay (ADA) requirements.

Polyclonal antibody development can be seamlessly integrated into a monoclonal project plan when the goal of having a matched pair is defined, or if ADA reagents are required.

Key benefits



Antigen analysis

Option to receive a custom report, prepared by an immunologist, to identify the right antigen strategy for any goal.



Detailed project plan

Identify goals, reagents, screening strategies and set contingency plans to ensure timely development.



MultiPure

Generate up to 1 mg of discovery-grade purified antibodies from fusion candidates during hybridoma development to select clones based on end use performance.



Characterization assays

Characterize antibody candidates beyond standard indirect ELISA screening, so only the right antibodies go to subcloning.



Technical support

Hands-on support from project managers, technical sales team and immunology experts at every project milestone.

Development & production

- Hybridoma antibody development
- Polyclonal antibody development
- ISO 13485:2016 certified
in vitro antibody manufacturing



Purification

- Protein A purification
- Antigen affinity purification
- SEC polishing

Characterization

- ELISA / Matched pair evaluation
- Western Blot / SDS-PAGE
- Cellular / Digital Imaging
- Immunohistochemistry
- Matrix evaluation
- Blocking / non-blocking profile
- Biophysical characterization

Develop antibodies with specific assay goals in mind



Accelerate timelines

Timely development is a high priority for most antibody development customers. Thorough project planning, rapid immunisation protocol (RIMMS), and efficient data analysis at every project milestone work together to accelerate project timelines. When goals change during the course of development, planning and communication allow BBI to be agile in making decisions and change the pathway to allow a project to be kept on track, meet new goals, and get the right result more quickly.

A typical project plan*

	1-2 WEEKS	4 WEEKS	2-3 MONTHS			6-8 WEEKS	1-2 WEEKS
Phase	Planning	Immunization	Fusion	General discovery reagents	Advanced screening	Subcloning & productions	Monoclonal assays
Activity	Antigen review Project planning	RIMMS protocol Serum screening	Primary screening Scale-up and cryopreservation of fusion product selections Secondary screening	MultiPure technology offers novel early access to purified samples	Matched pair evolution Blocking assays Matrix evaluation	Top-ranked fusion products subcloned Monoclonal cell line cryopreservation cGMP in vitro production	Analytical characterization of antibody(s) Fit-for-use performance evaluation
Deliverables	- Antigen analysis report - Project plan	- Serum titre data - Boosting strategy (if needed)	- Screening data - Banked cryo-vitals - Supernatant	- Discovery-scale purified antibody - Biotin-labelled conjugates (optional)	- Advanced screening report - Subcloning candidates identified	- Screening data - Assessment of stability - Pilot production recommendations	- Screening data - Assessment of stability - Performance characterization report summary

* Representative



What you can expect from BBI

Advanced screening capabilities

‘MultiPure’ allows customers to select clones based on specificity, sensitivity, matched pair compatibility, matrix compatibility, diversity and native recognition in the desired end-application.

ISO13485:2016 certified

In vitro antibody manufacturing and custom production at flexible scales according to ISO 13485:2016 guidelines.

Knowledge and experience

The antibody technical team brings over 27 years of deep expertise in immunology, antibody and immunoassay development to every project.

Unparalleled customer communication

Customers are informed of data at all project stages and provided analysis with recommendations needed to make goal-driven decisions.



Contact BBI Solutions today to develop the right antibodies for any application
www.bbisolutions.com or email info@bbisolutions.com
Int: +44 (0) 1495 363 000 USA: +1 207-797-5454 China: +86 (0) 21 6104 2216

Oct 2025/V4